A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Pain associated with cancer and chronic musculoskeletal disorders can be difficult to control. We used murine models of cancer and inflammatory muscle pain to examine whether the cannabinoid receptor agonist WIN55,212-2 reduces hyperalgesia originating in deep tissues. C3H/He mice were anesthetized and implanted with osteolytic NCTC clone 2472 cells into the humeri or injected with 4% carrageenan into the triceps muscles of both forelimbs. At the time of peak hyperalgesia, WIN55,212-2 (1-30mg/kg) or vehicle was administered intraperitoneally and forelimb grip force was measured 0.5-24h later. WIN55,212-2 produced time- and dose-related antihyperalgesia in both models. A 10mg/kg dose of WIN55,212-2 fully reversed carrageenan-evoked muscle hyperalgesia. However, 30mg/kg of WIN55,212-2 attenuated tumor-evoked hyperalgesia only approximately 50%. After controlling for the difference in magnitude of hyperalgesia between the two models, WIN55,212-2 was still more potent at reducing hyperalgesia in the inflammatory model. In the cancer pain model, the antihyperalgesic effect of WIN55,212-2 was partially blocked by pretreatment with the selective CB1 (SR141716A) but not the CB2 (SR144528) receptor antagonist. In contrast, both antagonists blocked antihyperalgesic effects of WIN55,212-2 on carrageenan-evoked muscle hyperalgesia. Catalepsy and loss of motor coordination, known side effects of cannabinoids, did not account for the antihyperalgesia produced by WIN55,212-2. These data show that cannabinoids attenuate deep tissue hyperalgesia produced by both cancer and inflammatory conditions. Interestingly, cannabinoids differentially modulated carrageenan- and tumor-evoked hyperalgesia in terms of potency and receptor subtypes involved suggesting that differences in underlying mechanisms may exist between these two models of deep tissue pain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ethical guidelines for investigations of experimental pain in conscious animals.
Zimmermann, M. (1983) · Pain · doi:10.1016/0304-3959(83)90201-4 · Cited by 7,762 · cited 1×
“All studies conformed to guidelines put forth by the International Association for the Study of Pain for the use of experimental animals (Zimmermann, 1983) and were approved by the University of Minnesota’s Institutional Animal Care and Use Committee.”
MethodMolecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092 · cited 2×
“Cannabinoids exert their effects via activation of CB1 receptors, located in the central nervous system (CNS) and on primary afferent fibers, and CB2 receptors located primarily on immune cells (Matsuda et al., 1990; Gerard et al., 1991; Munro et al., 1993).”
BackgroundStructure of a cannabinoid receptor and functional expression of the cloned cDNA
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., & Bonner, T. I. (1990) · Nature · doi:10.1038/346561a0 · Cited by 5,011
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“These two receptor subtypes have been cloned (Matsuda et al., 1990; Gerard et al., 1991; Munro et al., 1993) and endogenous ligands have been identified for both (Devane et al., 1992; Mechoulam et al., 1995; Sugiura et al., 1995; Hanus et al., 2001; Porter et al., 2002).”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Cannabinoid receptors and pain
Pertwee, R. G. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00031-9 · Cited by 741
Facci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632 · cited 1×
“CB2 receptors are present on mast cells in the periphery where their activation can inhibit degranulation (Facci et al., 1995).”
BackgroundThe analgesic properties of delta‐9‐tetrahydrocannabinol and codeine
Noyes, R., Brunk, S. F., Avery, D. H., & Canter, A. (1975) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197518184 · Cited by 378 · cited 1×
“Scattered reports suggest that cannabinoids exhibit analgesic effects in patients with cancer (Noyes et al., 1975; Staquet et al., 1978) and chronic muscle pain (Petro, 1980), but these evaluations have been of a limited nature.”
BackgroundHerzberg, U., Eliav, E., Bennett, G. J., & Kopin, I. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(96)13308-5 · Cited by 307 · cited 3×
“Similarly, the non-selective synthetic cannabinoid WIN55,212-2 attenuated nocifensive behaviors and both thermal and mechanical hyperalgesia produced by nerve injury (Herzberg et al., 1997).”
BackgroundMartin, W. J., Coffin, P. O., Attias, E., Balinsky, M., Tsou, K., & Walker, J. M. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01368-7 · Cited by 164
Cited by
Svendsen, K. B., Jensen, T. S., & Bach, F. W. (2004) · BMJ · doi:10.1136/bmj.38149.566979.ae · Cited by 500
Role of central dopamine in pain and analgesia
Wood, P. B. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.5.781 · Cited by 370
Ständer, S., Schmelz, M., Metze, D., Luger, T., & Rukwied, R. (2005) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2005.01.007 · Cited by 298
Lichtman, A. H., Shelton, C. C., Advani, T., & Cravatt, B. F. (2004) · Pain · doi:10.1016/j.pain.2004.01.022 · Cited by 301
“In addition, it has also been demonstrated that exogenous cannabinoids have anti-hyperalgesic effects in a chronic malignant pain model (Kehl et al., 2003).”
BackgroundActions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models
Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., & Vaughan, C. W. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706510 · Cited by 287
Metadata
- Authors
- Kehl, L. J., Hamamoto, D. T., Wacnik, P. W., Croft, D. L., Norsted, B. D., Wilcox, G. L., & Simone, D. A.
- Venue
- Pain
- Published
- 2003-05
- Volume
- 103
- Issue
- 1
- Pages
- 175-186
- ISSN
- 0304-3959 (ISSN-L)
- OpenAlex
- W2035980199
- Cited by
- 115
- References
- 13
- FWCI
- 6.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. https://app.cochat.ai/papers/10.1016/s0304-3959(02)00450-5
- The paper
- Kehl, L. J., Hamamoto, D. T., Wacnik, P. W., Croft, D. L., Norsted, B. D., Wilcox, G. L., & Simone, D. A. (2003). A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. https://doi.org/10.1016/s0304-3959(02)00450-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.